Scientists have discovered that the oral antiviral drug Obildesivir effectively prevents death in monkeys infected with the Ebola virus, showcasing a promising approach to control potential outbreaks. This drug could be a significant advancement in developing treatments that are easier to distribute and store compared to injectable therapies.
Recent research has indicated that an oral antiviral drug effectively prevents the death of monkeys infected with the Ebola virus. This discovery presents a significant opportunity to mitigate future outbreaks of this deadly virus, which has a mortality rate of approximately 90% for infected humans and primates. Notably, prior outbreaks, such as the one in West Africa from 2013 to 2016, resulted in 11,325 fatalities among 28,600 cases.
Previous methods to combat Ebola have included antibody-based therapies, but these have limitations, particularly due to the necessity of refrigeration for storage and distribution. Consequently, there is an urgent need to create oral tablet treatments, enabling swift and widespread distribution in regions with limited resources.
The scientists emphasized the advantages of oral antiviral medications: “Oral antiviral drugs offer several advantages over injectable treatments, including ease of supply, storage, distribution, and administration.”
The drug Obildesivir (ODV) was previously noted for its effectiveness against various RNA viruses, including Ebola, when administered within 24 hours of exposure. Initial studies utilized an intramuscular method of virus introduction, which advanced disease progression rapidly, thus complicating the assessment of the drug’s efficacy.
A recent study published in Science Advances demonstrated that Obildesivir provided 100% protection for rhesus monkeys exposed to the virulent Macuna strain of Ebola via mucosal membranes. Ten monkeys received daily doses of Obildesivir for ten days, and results showed 100% protection for the rhesus and 80% for crab-eating macaques.
Additionally, the disease progressed more slowly with the new administration technique, allowing researchers to investigate the drug’s effects more thoroughly. The treated monkeys exhibited increased expression of proteins that promote T-cell activation, improved anti-inflammatory responses, and reduced severe immune reactions.
Overall, the findings indicate the potential of Obildesivir as an oral post-exposure preventive treatment against Ebola. The researchers concluded: “These results suggest that Obildesivir treatment offers an opportunity to develop adaptive immunity while reducing excessive inflammation, which may prevent lethal outcomes.” They intend to explore how late-stage treatment with Obildesivir influences immune responses further.
In conclusion, the discovery of an oral antiviral drug, Obildesivir, demonstrates promising potential in preventing deadly Ebola infections in primates. The study highlights the necessity for accessible treatment options that can be distributed efficiently, particularly in resource-limited areas. The findings support the development of Obildesivir as an effective post-exposure treatment, potentially improving survival rates and reducing excessive inflammation in infected individuals.
Original Source: www.jordannews.jo
